Immunopathology of Chronic Critical Illness in Sepsis Survivors: Role of Abnormal Myelopoiesis
Overview
Affiliations
Sepsis remains the single most common cause of mortality and morbidity in hospitalized patients requiring intensive care. Although earlier detection and improved treatment bundles have reduced in-hospital mortality, long-term recovery remains dismal. Sepsis survivors who experience chronic critical illness often demonstrate persistent inflammation, immune suppression, lean tissue wasting, and physical and functional cognitive declines, which often last in excess of 1 year. Older patients and those with preexisting comorbidities may never fully recover and have increased mortality compared with individuals who restore their immunologic homeostasis. Many of these responses are shared with individuals with advanced cancer, active autoimmune diseases, chronic obstructive pulmonary disease, and chronic renal disease. Here, we propose that this resulting immunologic endotype is secondary to a persistent maladaptive reprioritization of myelopoiesis and pathologic activation of myeloid cells. Driven in part by the continuing release of endogenous alarmins from chronic organ injury and muscle wasting, as well as by secondary opportunistic infections, ongoing myelopoiesis at the expense of lymphopoiesis and erythropoiesis leads to anemia, recurring infections, and lean tissue wasting. Early recognition and intervention are required to interrupt this pathologic activation of myeloid populations.
Hotairm1 Controls S100A9 Protein Phosphorylation in Myeloid-Derived Suppressor Cells during Sepsis.
Bah I, Youssef D, Yao Z, McCall C, El Gazzar M J Clin Cell Immunol. 2024; 14(4).
PMID: 39665047 PMC: 11633817.
Yu Z, Qian Y J Thorac Dis. 2024; 16(10):6688-6698.
PMID: 39552902 PMC: 11565322. DOI: 10.21037/jtd-24-952.
Multiple organ failure: What you need to know.
Brakenridge S, Kornblith L, Cuschieri J J Trauma Acute Care Surg. 2024; .
PMID: 39225733 PMC: 11873179. DOI: 10.1097/TA.0000000000004419.
Development and optimization of a diluted whole blood ELISpot assay to test immune function.
Ungaro R, Xu J, Kucaba T, Rao M, Bergmann C, Brakenridge S J Immunol Methods. 2024; 533:113743.
PMID: 39147231 PMC: 11398710. DOI: 10.1016/j.jim.2024.113743.
The potential immunological mechanisms of sepsis.
Zhang X, Zhang Y, Yuan S, Zhang J Front Immunol. 2024; 15:1434688.
PMID: 39040114 PMC: 11260823. DOI: 10.3389/fimmu.2024.1434688.